



CHROMATOGRAPHY

MPC™ Ceramic Hydroxyfluoroapatite

- High physical and chemical stability
- Unmatched selectivity
- Clearance of impurities and aggregates in a single step
- Rapid and simple column packing

Separation of Impurities in a Single Step

The newest addition to Bio-Rad's line of ceramic apatite chromatography media is MPC ceramic hydroxyfluoroapatite. MPC is a second-generation CHT™ ceramic hydroxyapatite mixed-mode chromatography media, a composite of hydroxyapatite and fluoroapatite prepared by chemically substituting 25% of the hydroxyl groups of hydroxyapatite nanocrystals with a fluorine reagent. Its chemical formula is $\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_{1.5}(\text{F})_{0.5}$. The partial fluorination confers a more chemically stable form of the matrix during pH excursions that are inherent to buffer exchanges. MPC has unique separation properties, unmatched selectivity, and resolution similar to CHT, including binding capacity (Tables 1 and 2), protein separations (Figure 1), and clearance (Figures 2 and 3, Table 3). MPC is 40 μm and is directly comparable to CHT Type I, 40 μm (Tables 1 and 2).

Mechanism of Action and Standard Chromatography

MPC interacts with biomolecules by multiple modes. Cation exchange occurs when negatively charged phosphate groups interact with protein amino groups. Much stronger coordination complexes can form between carboxyl clusters, phosphoryl moieties, or both on biomolecules and the calcium sites on MPC via metal affinity. Repulsion effects and the geometric charge distribution on MPC provide unique selectivity. Typically, acidic, basic, and neutral proteins are bound to MPC using low ionic strength phosphate buffer. Elution is accomplished through the use of a sodium chloride or phosphate gradient of increasing strength or via similar step elutions. Regeneration of the support with phosphate buffers at neutral pH is followed by sanitization with up to 2 N NaOH. Regardless of greater chemical stability, we recommend implementing pH mitigation steps, for example, the surface neutralization system (SNS). A pilot-scale study with MPC using SNS achieved 125 cycles. For more detailed information, refer to the CHT user's guide at www.bio-rad.com/CHTGuide.

Table 1. Specifications.

	CHT Type I, 40 μm	MPC
Functional groups	Ca^{2+} , PO_4 , OH	Ca^{2+} , PO_4 , OH, F
Observed dynamic binding capacity lysozyme (Lys)	≥ 25 mg Lys/g CHT	≥ 25 mg Lys/g MPC
Nominal pore diameter	600–800 Å	600–800 Å
Maximum backpressure	100 bar (1,500 psi)	100 bar (1,500 psi)
Nominal mean particle size	40 \pm 4 μm	40 \pm 4 μm
Tap settled density* (g/ml tap settled bed)	0.63 g/ml	0.72 g/ml

* Under ideal conditions.



Table 2. Characteristics.

	CHT Type I, 40 μ m	MPC
Observed dynamic binding capacity IgG	25–60 mg IgG/ml CHT*	25–50 mg IgG/ml MPC**
Typical linear flow rate range	50–1,000 cm/hr	50–1,000 cm/hr
pH stability	6.5–14 pH	6.5–14 pH
Base stability	At least 1 year in 0.1 N NaOH	At least 1 year in 0.1 N NaOH
Regeneration	0.4–0.5 M sodium phosphate, pH 7–7.5, is generally sufficient. If higher concentrations are needed, use potassium phosphate	0.4–0.5 M sodium phosphate, pH 7–7.5, is generally sufficient. If higher concentrations are needed, use potassium phosphate
Autoclavability (bulk)	121°C, 20 min in phosphate buffer, pH 7	121°C, 20 min in phosphate buffer, pH 7
Sanitization	1–2 N NaOH	1–2 N NaOH
Recommended column storage	0.1 N NaOH	0.1 N NaOH

* 40 μ m particles, 300 cm/hr, 5 mM sodium phosphate, pH 6.5.

** 40 μ m particles, 300 cm/hr, 5 mM sodium phosphate, 25 mM NaCl, pH 6.5.




Fig. 1. Separation of protein standards. MPC separates the standard protein mixture similarly to CHT Type I, 40 μ m. Sample: 6 mg of ovalbumin, 3 mg of myoglobin, 3 mg of α -chymotrypsinogen A, and 3 mg of cytochrome C in 1.5 ml 10 mM sodium phosphate (NaPi), pH 6.8. CHT column: 0.5 x 10.3 cm, packed bed volume 2 ml; MPC column: 0.5 x 10.4 cm, packed bed volume 2 ml. Protocol: 1.55 ml/min; 400 mM NaPi, pH 6.8, 5 column volumes (CV); 10 mM NaPi, pH 6.8, 15 CV; load volume 50 μ l; linear gradient elution 0 to 75% 400 mM NaPi, pH 6.8, over 15 CV; strip 400 mM NaPi, pH 6.8, 5 CV; sanitization 1 N NaOH, 5 CV. CHT (—); MPC (—).




Fig. 2a. MAb-S size exclusion chromatography (SEC) profile of starting material. SEC profile shows the higher molecular weight impurities (dimers/aggregates) and monomers in the starting material (material applied to the second step (Figure 2b) using CHT or MPC). Sample: 2.9 mg/ml mAb-S in 10 mM NaPi, pH 7. Column: 300 x 7.8 mm, Bio-Sil[®] SEC 250 HPLC. Protocol: 1 ml/min; equilibration in 1 ml of 0.1 M NaPi, 0.15 M NaCl, 0.02% azide, pH 7; injection volume 0.1 ml; elution in 15 ml of 0.1 M NaPi, 0.15 M NaCl, 0.02% azide, pH 7.




Fig. 2b. MAb-S purification profile. Elution profile shows separation of the monomer from higher molecular weight impurities. Sample: 7.26 mg mAb-S/ml packed bed in 5 ml 10 mM NaPi, pH 7. Column: 0.5 x 10 cm, packed bed volume 2.1 ml of UNOsphere SUPRA[™] rProtein A media. Protocol: 0.5 ml/min; 10 mM NaPi, pH 7, 5 column volumes (CV); load volume 5 ml; 10 mM NaPi, pH 7, 5 CV; linear gradient elution 0 to 100% 10 mM NaPi, 1 M NaCl, pH 7, over 40 CV; strip 10 mM NaPi, 1 M NaCl, pH 7, 5 CV; sanitization 1 N NaOH, 5 CV. CHT (—); MPC (—).




Fig. 2c. SEC profile of pooled monomer fractions. The SEC profile of the pooled fractions confirms aggregate clearance from the monomer. Column: 300 x 7.8 mm, Bio-Sil SEC 250 HPLC. Protocol: 1 ml/min; 100 mM NaPi, 150 mM NaCl, 0.02% azide, pH 7, 1 ml; load volume 0.1 ml; elution 100 mM NaPi, 150 mM NaCl, 0.02% azide, pH 7, 15 ml. CHT (—); MPC (—).




Fig. 3a. MAb-G SEC profile of starting material. SEC profile shows the higher molecular weight impurities (dimers/aggregates) and monomers in the starting material (material applied to the second step (Figure 3b) using CHT or MPC). Sample: 4.41 mg/ml mAb-S in 10 mM NaPi, pH 7. Column: 300 x 7.8 mm, Bio-Sil SEC 250 HPLC. Protocol: 1 ml/min; equilibration in 1 ml of 0.1 M NaPi, 0.15 M NaCl, 0.02% azide, pH 7; injection volume 0.1 ml; elution in 15 ml of 0.1 M NaPi, 0.15 M NaCl, 0.02% azide, pH 7.




Fig. 3b. MAb-G purification profile. Elution profile shows separation of the monomer from higher molecular weight impurities. Protocol as described in Figure 2b. CHT (—); MPC (—).




Fig. 3c. SEC profile of pooled monomer fractions. The SEC profile of the pooled fractions confirms aggregate clearance from the monomer. Protocol as described in Figure 2c. CHT (—); MPC (—).

Table 3. Quantified data from all assays. All pooled fractions and mAb starting material purified on MPC and CHT were analyzed for host cell protein (HCP ELISA kit, Cygnus Technologies), for dsDNA (PicoGreen dsDNA quantitation kit, Invitrogen Corporation), for protein A leachables (Protein A ELISA kit, Cygnus Technologies), and for aggregate clearance by SEC (Bio-Sil SEC 250, Bio-Rad Laboratories, Inc).

Sample	IgG Concentration, mg/ml	Protein A, ppm	HCP, ppm	DNA, ppm	Dimer/Aggregate, %
MAb-S					
Protein A eluate	2.90	33	24	21	21.62
CHT pool	0.40	<0.6	<2	2.6	<0.03
MPC pool	0.46	<0.5	<2	2.8	<0.03
MAb-G					
Protein A eluate	4.41	17	<2	0.82	4.39
CHT pool	0.91	<0.3	<1	1.4	<0.03
MPC pool	0.77	<0.3	<1	1.4	<0.03




Fig. 4. Elution profiles of five acidic proteins. CHT and MPC produce similar elution characteristics for the five acidic proteins studied. Samples: porcine carboxypeptidase B (CBP), pI 4.6–5.2, pepsin pI 2.9, fetuin, pI 3.3, BSA, pI 4.9, and apoferritin, pI 5.0–5.5, each prepared to a final concentration of 2–3 mg/ml in water. Column: 0.7 x 2.6 cm, packed bed volume 1 ml, executed using a BioLogic DuoFlow™ system and software. Protocol: 300 cm/hr; load volume 100 μ l; linear gradient elution 0 to 100% 0.02 M HEPES, 0.01 M NaPi, pH 6.5, to 0.02 M HEPES, 0.4 M NaPi, pH 6.5, over 20 CV. CHT (—); MPC (—).




Fig. 5. Nucleic acids separation profile. Elution profile shows separation of ADP and ATP. Sample: 1 mg each of adenosine, AMP, ADP, and ATP mixture dissolved in 1 ml of 10 mM NaPi, pH 6.8, filtered with 0.22 μ m membrane. Column: 0.4 x 10 cm. Protocol: 1 ml/min; load volume 0.03 ml; wash 10 mM NaPi, pH 6.8, 2 CV; linear gradient elution 0 to 75% 400 mM NaPi, pH 6.8, over 12 CV; strip 400 mM NaPi, pH 6.8, 4 CV. CHT (—); MPC (—).

Storage

MPC ceramic hydroxyfluoroapatite should be stored in 0.1 N NaOH at room temperature. In dry powder form, MPC ceramic hydroxyfluoroapatite should be stored in a secured, closed container at room temperature.

Technical Assistance

For more detailed information on process step development, use recommended steps as described in the CHT Applications Guide (www.bio-rad.com/CHTGuide). Regulatory support file is available upon request. Bio-Rad Laboratories is an ISO 9001 registered corporation. For additional information and technical assistance, contact your local Bio-Rad office. In the USA and Canada, call 1-800-4BIORAD. You can also send an email to lsg_techserv_us@bio-rad.com. Visit us on the Web at www.bio-rad.com for more information on Bio-Rad's complete line of process chromatography supports.

Ordering Information

Catalog # Description

MPC Ceramic Hydroxyfluoroapatite, Type I

158-0200	MPC Ceramic Hydroxyfluoroapatite, 40 µm, Type I, 10 g
157-0200	MPC Ceramic Hydroxyfluoroapatite, 40 µm, Type I, 100 g
157-0201	MPC Ceramic Hydroxyfluoroapatite, 40 µm, Type I, 1 kg
157-0205	MPC Ceramic Hydroxyfluoroapatite, 40 µm, Type I, 5 kg

Foresight™ Columns

732-4737	Foresight™ MPC™ Type I Column, 40 µm, 1 ml
732-4757	Foresight MPC Type I Column, 40 µm, 5 ml

Foresight Plates*

732-4785	Foresight MPC Type I Plates, 40 µm, 20 µl
----------	---

Foresight RoboColumn Units**

732-4828	Foresight MPC Type I RoboColumn Units, 40 µm, 200 µl
732-4829	Foresight MPC Type I RoboColumn Units, 40 µm, 600 µl

* Package size: 2 x 96-well plates

** Package size: one row of eight columns

Related Items

CHT Ceramic Hydroxyapatite, Type I

158-2000	CHT Ceramic Hydroxyapatite, 20 µm, Type I, 10 g
157-0020	CHT Ceramic Hydroxyapatite, 20 µm, Type I, 100 g
157-0021	CHT Ceramic Hydroxyapatite, 20 µm, Type I, 1 kg
157-0025	CHT Ceramic Hydroxyapatite, 20 µm, Type I, 5 kg
158-4000	CHT Ceramic Hydroxyapatite, 40 µm, Type I, 10 g
157-0040	CHT Ceramic Hydroxyapatite, 40 µm, Type I, 100 g
157-0041	CHT Ceramic Hydroxyapatite, 40 µm, Type I, 1 kg
157-0045	CHT Ceramic Hydroxyapatite, 40 µm, Type I, 5 kg
158-8000	CHT Ceramic Hydroxyapatite, 80 µm, Type I, 10 g
157-0080	CHT Ceramic Hydroxyapatite, 80 µm, Type I, 100 g
157-0081	CHT Ceramic Hydroxyapatite, 80 µm, Type I, 1 kg
157-0085	CHT Ceramic Hydroxyapatite, 80 µm, Type I, 5 kg

Catalog # Description

CHT Ceramic Hydroxyapatite, Type II

158-2200	CHT Ceramic Hydroxyapatite, 20 µm, Type II, 10 g
157-2000	CHT Ceramic Hydroxyapatite, 20 µm, Type II, 100 g
157-2100	CHT Ceramic Hydroxyapatite, 20 µm, Type II, 1 kg
157-2500	CHT Ceramic Hydroxyapatite, 20 µm, Type II, 5 kg
158-4200	CHT Ceramic Hydroxyapatite, 40 µm, Type II, 10 g
157-4000	CHT Ceramic Hydroxyapatite, 40 µm, Type II, 100 g
157-4100	CHT Ceramic Hydroxyapatite, 40 µm, Type II, 1 kg
157-4500	CHT Ceramic Hydroxyapatite, 40 µm, Type II, 5 kg
158-8200	CHT Ceramic Hydroxyapatite, 80 µm, Type II, 10 g
157-8000	CHT Ceramic Hydroxyapatite, 80 µm, Type II, 100 g
157-8100	CHT Ceramic Hydroxyapatite, 80 µm, Type II, 1 kg
157-8500	CHT Ceramic Hydroxyapatite, 80 µm, Type II, 5 kg

Foresight Columns

732-4735	Foresight™ CHT™ Type I Column, 40 µm, 1 ml
732-4755	Foresight CHT Type I Column, 40 µm, 5 ml
732-4736	Foresight CHT Type II Column, 40 µm, 1 ml
732-4756	Foresight CHT Type II Column, 40 µm, 5 ml

Foresight Plates*

732-4716	Foresight CHT Type I Plates, 40 µm, 20 µl
732-4718	Foresight CHT Type II Plates, 40 µm, 20 µl

Foresight RoboColumn Units**

732-4822	Foresight CHT Type I RoboColumn Units, 40 µm, 200 µl
732-4823	Foresight CHT Type I RoboColumn Units, 40 µm, 600 µl
732-4825	Foresight CHT Type II RoboColumn Units, 40 µm, 200 µl
732-4826	Foresight CHT Type II RoboColumn Units, 40 µm, 600 µl

* Package size: 2 x 96-well plates

** Package size: one row of eight columns

For More Information

Request or download bulletins 6086 and 5667

PicoGreen is a trademark of Invitrogen Corporation.



**Bio-Rad
Laboratories, Inc.**

*Life Science
Group*

Web site www.bio-rad.com **USA** 800 424 6723 **Australia** 61 2 9914 2800 **Austria** 01 877 89 01 **Belgium** 09 385 55 11 **Brazil** 55 11 5044 5699
Canada 905 364 3435 **China** 86 21 6169 8500 **Czech Republic** 420 241 430 532 **Denmark** 44 52 10 00 **Finland** 09 804 22 00
France 01 47 95 69 65 **Germany** 089 31 884 0 **Greece** 30 210 9532 220 **Hong Kong** 852 2789 3300 **Hungary** 36 1 459 6100 **India** 91 124 4029300
Israel 03 963 6050 **Italy** 39 02 216091 **Japan** 03 6361 7000 **Korea** 82 2 3473 4460 **Mexico** 52 555 488 7670 **The Netherlands** 0318 540666
New Zealand 64 9 415 2280 **Norway** 23 38 41 30 **Poland** 48 22 331 99 99 **Portugal** 351 21 472 7700 **Russia** 7 495 721 14 04
Singapore 65 6415 3188 **South Africa** 27 861 246 723 **Spain** 34 91 590 5200 **Sweden** 08 555 12700 **Switzerland** 026674 55 05
Taiwan 886 2 2578 7189 **Thailand** 800 88 22 88 **United Kingdom** 020 8328 2000